Influenza injectable trivalent TIV Severe allergic reaction eg anaphylaxis

Influenza injectable trivalent tiv severe allergic

This preview shows page 1 out of 1 page.

Influenza, injectable trivalent (TIV) • Severe allergic reaction (e.g., anaphylaxis) after a previous vaccine dose or to a vaccine component, including egg protein • Moderate or severe acute illness with or without fever • History of GBS within 6 wks of previous influenza vaccine • Moderate or severe acute illness with or without fever Pneumococcal polysaccharide (PPSV) • Severe allergic reaction (e.g., anaphylaxis) after a previous vaccine dose or to a vaccine component Hepatitis A (HepA) • Severe allergic reaction (e.g., anaphylaxis) after a previous vaccine dose or to a vaccine component • Moderate or severe acute illness with or without fever • Pregnancy Influenza, live atten- uated (LAIV) 2 • Severe allergic reaction (e.g., anaphylaxis) after a previous vaccine dose or to a vaccine component, including egg protein • Pregnancy • Known severe immunodeficiency (e.g., hematologic and solid tumors; receiving chemotherapy; congenital immunodeficiency; long-term immunosuppressive therapy 3 ; or patients with HIV infection who are severely immunocompromised) • Certain chronic medical conditions 5 • Moderate or severe acute illness with or without fever • History of GBS within 6 wks of previous influenza vaccine • Receipt of specific antivirals (i.e., amantadine, rimantadine, zanamivir, or oseltamivir) 48 hours before vaccination. Avoid use of these antiviral drugs for 14 days after vaccination. • Close contact with an immunosuppressed person when the person requires protec- tive isolation Footnotes
Image of page 1

You've reached the end of your free preview.

Want to read the whole page?

  • Summer '13
  • Karla Garcia
  • severe allergic reaction, severe acute illness

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture